Special Issue "Tumor Xenografts"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 May 2019

Special Issue Editors

Guest Editor
Dr. Bonnie Hylander

Department of Immunology, Roswell Park Cancer Institute, Buffalo, United States
Website | E-Mail
Interests: mouse models, tumor immunology, stress, housing temperature
Guest Editor
Prof. Dr. Elizabeth Repasky

Department of Immunology, Roswell Park Cancer Institute, Buffalo, United States
Website | E-Mail
Interests: tumor immunology, radiation, anti-tumor immune response, housing temperature stress

Special Issue Information

Dear Colleague,

Mouse models are used in preclinical and translational research to investigate events that initiate and drive cancer progression, as well as to evaluate new therapies. There is a wide spectrum of mouse models to choose from, depending on the intended experimental purpose. However, there is a growing realization that the therapeutic results obtained using mouse models often do not predict efficacy in the clinic. One approach to improving the modeling of patient tumors and their therapeutic responses has been to develop cohorts of patient-derived xenograft tumors (PDX models). PDX models, engrafted into immunodeficient SCID mice, are thought to best represent the diversity and heterogeneity of the patient population. A major shortcoming of these models is the lack of adaptive immune responses in SCID mice, although this is being addressed by the use of so-called humanized SCID mice. The current status of PDX models is the focus of this Special Issue. We welcome articles that will review and present up-to-date information on the characterization and advantages of PDX models, especially as to how well they actually recapitulate the diversity of patient tumors, the evaluation of new therapeutics, biomarker discovery, use as avatars in personalized medicine approaches, and ideas as to how to improve these valuable models.

Dr. Bonnie Hylander
Prof. Dr. Elizabeth Repasky
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PDX
  • patient xenograft
  • avatar
  • mouse model
  • tumorografts

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle Membrane Lipidome Reorganization and Accumulation of Tissue DNA Lesions in Tumor-Bearing Mice: An Exploratory Study
Cancers 2019, 11(4), 480; https://doi.org/10.3390/cancers11040480
Received: 8 February 2019 / Revised: 1 April 2019 / Accepted: 2 April 2019 / Published: 4 April 2019
PDF Full-text (1709 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Increased rates of reactive oxygen/nitrogen species (ROS/RNS) are involved in almost all cancer types, associated with tumor development and progression, causing damage to biomolecules such as proteins, nucleic acids and membrane lipids, in different biological compartments. We used a human tumor xenograft mouse [...] Read more.
Increased rates of reactive oxygen/nitrogen species (ROS/RNS) are involved in almost all cancer types, associated with tumor development and progression, causing damage to biomolecules such as proteins, nucleic acids and membrane lipids, in different biological compartments. We used a human tumor xenograft mouse model to evaluate for the first time in parallel the remodeling of fatty acid moieties in erythrocyte membrane phospholipids and the level of ROS-induced DNA lesions in liver and kidney tissues. Using liquid chromatography tandem mass spectrometry the 5′R and 5′S diastereoisomers of 5′,8-cyclo-2′-deoxyadenosine and 5′,8-cyclo-2′-deoxyguanosine, together with 8-oxo-7,8-dihydro-2′-deoxyadenosine, were determined in mice at young (4- and 5-weeks) and old (17-weeks) ages and compared with control SCID mice without tumor implantation. Tumor-bearing mice showed a higher level of ROS-damaged nucleosides in genomic DNA as the age and tumor progress, compared to controls (1.07–1.53-fold in liver and 1.1–1.4-fold in kidney, respectively). The parallel fatty acid profile of erythrocyte membranes showed a profound lipid remodeling during tumor and age progression consisting of PUFA consumption and SFA enrichment (ca 28% and 58%, respectively, in late stage tumor-bearing mice), markers of enhanced oxidative and proliferative processes, respectively. Membrane lipid remodeling and ROS-induced DNA lesions may be combined to afford an integrated scenario of cancer progression and ageing, reinforcing a holistic vision among molecular markers rather than the biomarker identification in a single compartment. Full article
(This article belongs to the Special Issue Tumor Xenografts)
Figures

Graphical abstract

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top